# **Rozlytrek**<sup>®</sup> Entrectinib Hard capsules



## NAME OF THE MEDICINAL PRODUCT

Rozlytrek 100 mg Rozlytrek 200 mg

## QUALITATIVE AND QUANTITATIVE COMPOSITION

<u>Rozlytrek 100 mg hard capsules</u> Each hard capsule contains 100 mg of entrectinib. *Excipient(s) with known effect* Each hard capsule contains 65 mg lactose.

<u>Rozlytrek 200 mg hard capsules</u>
Each hard capsule contains 200 mg of entrectinib. *Eexcipient(s) with known effect*Each hard capsule contains 130 mg lactose, and 0.6 mg of the azo colouring agent sunset yellow FCF (E110).

## For the full list of excipients, see section 11.

## 1 INDICATIONS AND USAGE

**1.1** Rozlytrek is indicated for the treatment of adults with solid tumors that:

- have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation
- are metastatic or where surgical resection is likely to result in severe morbidity, and
- have either progressed following treatment or have no satisfactory alternative therapy.

**1.2** Rozlytrek is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.

## 2 DOSAGE AND ADMINISTRATION

## 2.1 PATIENT SELECTION

Select patients for the treatment of metastatic NSCLC with ROZLYTREK based on the presence of *ROS1* rearrangement(s) in tumor specimens [see Clinical Studies (14.1)].

Select patients for treatment of locally advanced or metastatic solid tumors with ROZLYTREK based on the presence of a *NTRK* gene fusion [see Clinical Studies (14.2)].

## 2.2 RECOMMENDED DOSAGE FOR *ROS1*-POSITIVE NON-SMALL CELL LUNG CANCER

The recommended dosage of ROZLYTREK is 600 mg orally once daily with or without food until disease progression or unacceptable toxicity.

## 2.3 RECOMMENDED DOSAGE FOR *NTRK* GENE FUSION-POSITIVE SOLID TUMORS

#### <u>Adults</u>

The recommended dosage of ROZLYTREK in adults is 600 mg orally once daily with or without food until disease progression or unacceptable toxicity.

#### 2.4 DOSAGE MODIFICATIONS FOR ADVERSE REACTIONS

The recommended dosage reductions for adverse reactions are provided in Table 1.

#### Table 1: Recommended Dose Reductions for ROZLYTREK Adverse Reactions

Action	Adults (Orally once daily)
First dose reduction	400 mg
Second dose reduction*	200 mg

\*For a subsequent modification, permanently discontinue ROZLYTREK in patients who are unable to tolerate ROZLYTREK after two dose reductions.

Table 2 describes dosage modifications for specific adverse reactions.

#### Table 2: Recommended Dosage Modifications for ROZLYTREK for Adverse Reactions

Adverse Reaction	Severity*	Dosage Modification	
Congestive Heart Failure	Grade 2 or 3	• Withhold ROZLYTREK until recovered to less than or equal to Grade 1.	
[see Warnings and		• Resume at reduced dose.	
Precautions (5.1)]	Grade 4	• Permanently discontinue ROZLYTREK.	
Central Nervous System Effects	Intolerable Grade 2	• Withhold ROZLYTREK until recovery to less than or equal to Grade 1 or to baseline.	
[see Warnings and Precautions (5.2)]		• Resume at same dose or reduced dose, as clinically appropriate.	
	Grade 3	• Withhold ROZLYTREK until recovery to less than or equal to Grade 1 or to baseline.	
		• Resume at reduced dose.	
	Grade 4	Permanently discontinue ROZLYTREK.	

<b>Adverse Reaction</b>	Severity*	Dosage Modification	
Hepatotoxicity [see Warnings and Precautions (5.4)]	Grade 3	<ul> <li>Withhold ROZLYTREK until recovery to less than or equal to Grade 1 or to baseline.</li> <li>Resume at same dose if resolution occurs within 4 weeks.</li> <li>Permanently discontinue if adverse reaction does not resolve within 4 weeks.</li> <li>Resume at a reduced dose for recurrent Grade 3 events that resolve within 4 weeks.</li> </ul>	
	Grade 4	<ul> <li>Withhold ROZLYTREK until recovery to less than or equal to Grade 1 or to baseline.</li> <li>Resume at reduced dose if resolution occurs within 4 weeks.</li> <li>Permanently discontinue if adverse reaction does not resolve within 4 weeks.</li> <li>Permanently discontinue for recurrent Grade 4 events.</li> </ul>	
	ALT or AST greater than 3 times ULN with concurrent total bilirubin greater than 1.5 times ULN (in the absence of cholestasis or hemolysis).	Permanently discontinue ROZLYTREK.	
Hyperuricemia [see Warnings and Precautions (5.5)]	Symptomatic or Grade 4	<ul> <li>Initiate urate-lowering medication.</li> <li>Withhold ROZLYTREK until improvement of signs or symptoms.</li> <li>Resume ROZLYTREK at same or reduced dose.</li> </ul>	
QT Interval Prolongation [see Warnings and Precautions (5.6)]	QTc greater than 500 ms	<ul> <li>Withhold ROZLYTREK until QTc interval recovers to baseline.</li> <li>Resume at same dose if factors that cause QT prolongation are identified and corrected.</li> <li>Resume at reduced dose if other factors that cause QT prolongation are <u>not</u> identified.</li> </ul>	
	Torsade de pointes; polymorphic ventricular tachycardia; signs/symptoms of serious arrhythmia	• Permanently discontinue ROZLYTREK.	

Adverse Reaction	Severity*	Dosage Modification	
Vision Disorders [see Warnings and Precautions (5.7)]	Grade 2 or above	<ul> <li>Withhold ROZLYTREK until improvement or stabilization.</li> <li>Resume at same dose or reduced dose, as clinically appropriate.</li> </ul>	
Anemia or Neutropenia [see	Grade 3 or 4	<ul> <li>Withhold ROZLYTREK until recovery to less than or equal to Grade 2.</li> </ul>	
Adverse Reactions (6.1)]		• Resume at the same dose or reduced dose, as clinically appropriate.	
Other Clinically Relevant Adverse Reactions	Grade 3 or 4	• Withhold ROZLYTREK until adverse reaction resolves or improves to recovery or improvement to Grade 1 or baseline.	
		• Resume at the same or reduced dose, if resolution occurs within 4 weeks.	
		• Permanently discontinue if adverse reaction does not resolve within 4 weeks.	
		• Permanently discontinue for recurrent Grade 4 events.	

\*Severity as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0.

### 2.5 DOSAGE MODIFICATIONS FOR DRUG INTERACTIONS

#### Moderate and Strong CYP3A Inhibitors

#### Adults

Avoid coadministration of ROZLYTREK with moderate or strong CYP3A inhibitors. If coadministration cannot be avoided, reduce the ROZLYTREK dose as follows:

- Moderate CYP3A Inhibitors: 200 mg orally once daily
- *Strong CYP3A Inhibitors*: 100 mg orally once daily

After discontinuation of a strong or moderate CYP3A inhibitor for 3 to 5 elimination half-lives, resume the ROZLYTREK dose that was taken prior to initiating the CYP3A inhibitor [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].

#### 2.6 ADMINISTRATION

Swallow capsules whole. Do not open, crush, chew, or dissolve the contents of the capsule since the capsule content has a bitter taste.

If a patient misses a dose, instruct patients to make up that dose unless the next dose is due within 12 hours.

If a patient vomits immediately after taking a dose, instruct patients to repeat that dose.

#### **3 DOSAGE FORMS AND STRENGTHS**

Hard capsules:

- 100 mg: Size 2 yellow opaque body and cap, with "ENT 100" printed in blue ink on body.
- 200 mg: Size 0 orange opaque body and cap, with "ENT 200" printed in blue ink on body.

## 4 CONTRAINDICATIONS

## Hypersensitivity to the active substance or to any of the excipients listed in section 11.

## 5 WARNINGS and PRECAUTIONS

## 5.1 CONGESTIVE HEART FAILURE

Among the 355 patients who received ROZLYTREK across clinical trials, congestive heart failure (CHF) occurred in 3.4% of patients, including Grade 3 (2.3%) *[see Adverse Reactions (6.1)]*. In clinical trials, baseline cardiac function and routine cardiac monitoring other than electrocardiograms (ECGs) were not conducted and eligibility criteria excluded patients with symptomatic CHF, myocardial infarction, unstable angina, and coronary artery bypass graft within 3 months of study entry. Among the 12 patients with CHF, the median time to onset was 2 months (range: 11 days to 12 months). ROZLYTREK was interrupted in 6 of these patients (50%) and discontinued in 2 of these patients (17%). CHF resolved in 6 patients (50%) following interruption or discontinuation of ROZLYTREK and institution of appropriate medical management. In addition, myocarditis in the absence of CHF was documented in 0.3% of patients.

Assess left ventricular ejection fraction (LVEF) prior to initiation of ROZLYTREK in patients with symptoms or known risk factors for CHF. Monitor patients for clinical signs and symptoms of CHF, including shortness of breath and edema. For patients with myocarditis, with or without a decreased ejection fraction, MRI or cardiac biopsy may be required to make the diagnosis. For patients with new onset or worsening CHF, withhold ROZLYTREK, institute appropriate medical management, and reassess LVEF. Based on the severity of CHF or worsening LVEF, resume ROZLYTREK at a reduced dose upon recovery to baseline or permanently discontinue [see Dosage and Administration (2.4)].

## 5.2 CENTRAL NERVOUS SYSTEM EFFECTS

A broad spectrum of central nervous system (CNS) adverse reactions occurred in patients receiving ROZLYTREK, including cognitive impairment, mood disorders, dizziness, and sleep disturbances.

Among the 355 patients who received ROZLYTREK across clinical trials, 96 (27%) experienced cognitive impairment; symptoms occurred within 3 months of starting ROZLYTREK in 74 (77%). Cognitive impairment included cognitive disorders (8%), confusional state (7%), disturbance in attention (4.8%), memory impairment (3.7%), amnesia (2.5%), aphasia (2.3%), mental status changes (2%), hallucinations (1.1%), and delirium (0.8%). Grade 3 cognitive adverse reactions occurred in 4.5% of patients. Among the 96 patients with cognitive impairment, 13% required a dose reduction, 18% required dose interruption and 1% discontinued ROZLYTREK due to cognitive adverse reactions.

Among the 355 patients who received ROZLYTREK across clinical trials, 36 (10%) experienced mood disorders. The median time to onset of mood disorders was 1 month (range: 1 day to 9 months). Mood disorders occurring in  $\geq$  1% of patients included anxiety (4.8%), depression (2.8%) and agitation (2%). Grade 3 mood disorders occurred in 0.6% of patients. One completed suicide was reported 11 days after treatment had ended. Among the 36 patients who experienced mood disorders, 6% required a dose reduction, 6% required dose interruption and no patients discontinued ROZLYTREK due to mood disorders.

Dizziness occurred in 136 (38%) of the 355 patients. Among the 136 patients who experienced dizziness, Grade 3 dizziness occurred in 2.2% of patients. Ten percent of patients required a dose reduction, 7% required dose interruption and 0.7% discontinued ROZLYTREK due to dizziness.

Among the 355 patients who received ROZLYTREK across clinical trials, 51 (14%) experienced sleep disturbances. Sleep disturbances included insomnia (7%), somnolence (7%), hypersomnia (1.1%), and sleep disorder (0.3%). Grade 3 sleep disturbances occurred in 0.6% of patients. Among the 51 patients who experienced sleep disturbances, 6% required a dose reduction and no patients discontinued ROZLYTREK due to sleep disturbances.

The incidence of CNS adverse reactions was similar in patients with and without CNS metastases; however, the incidence of dizziness (38% vs 31%), headache (21% vs 13%), paresthesia (20% vs 6%), balance disorder (13% vs 4%), and confusional state (11% vs 2%) appeared to be increased in patients with CNS metastases who had received prior CNS irradiation (N = 90) compared to those who did not (N = 48).

Advise patients and caregivers of these risks with ROZLYTREK. Advise patients not to drive or operate hazardous machinery if they are experiencing CNS adverse reactions. Withhold and then resume at same or reduced dose upon improvement, or permanently discontinue ROZLYTREK based on severity [see Dosage and Administration (2.4)].

# 5.3 SKELETAL FRACTURES

ROZLYTREK increases the risk of fractures. In an expanded safety population that included 338 adult patients who received ROZLYTREK across clinical trials, 5% of adult patients experienced fractures. In adult patients, some fractures occurred in the setting of a fall or other trauma to the affected area. In general, there was inadequate assessment for tumor involvement at the site of fracture; however, radiologic abnormalities possibly indicative of tumor involvement were reported in some patients. Most fractures were hip or other lower extremity fractures (e.g., femoral or tibial shaft). In a limited number of patients, bilateral femoral neck fractures occurred. The median time to fracture was 3.8 months (range 0.3 to 18.5 months) in adults. ROZLYTREK was interrupted in 41% of adults due to fractures. No patients discontinued ROZLYTREK due to fractures.

Promptly evaluate patients with signs or symptoms (e.g., pain, changes in mobility, deformity) of fractures. There are no data on the effects of ROZLYTREK on healing of known fractures and risk of future fractures.

## **5.4 ΗΕΡΑΤΟΤΟΧΙCITY**

Among the 355 patients who received ROZLYTREK, increased AST of any grade occurred in 42% of patients and increased ALT of any grade occurred in 36%. Grade 3 – 4 increased AST or ALT occurred in 2.5% and 2.8% of patients, respectively; the incidence may be underestimated as 4.5% of patients had no post-treatment liver function tests *[see Adverse Reactions (6.1)]*. The median time to onset of increased AST was 2 weeks (range: 1 day to 29.5 months). The median time to onset of increased ALT was 2 weeks (range: 1 day to 9.2 months). Increased AST or ALT leading to dose interruptions or reductions occurred in 0.8% and 0.8% of patients, respectively. ROZLYTREK was discontinued due to increased AST or ALT in 0.8% patients.

Monitor liver tests, including ALT and AST, every 2 weeks during the first month of treatment, then monthly thereafter, and as clinically indicated. Withhold or permanently discontinue ROZLYTREK based on the severity. If withheld, resume ROZLYTREK at the same or reduced dose [see Dosage and Administration (2.4)].

## 5.5 HYPERURICEMIA

Among 355 patients who received ROZLYTREK across clinical trials, 32 patients (9%) experienced hyperuricemia reported as adverse reactions with symptoms, as well as elevated uric acid levels. Grade 4 hyperuricemia occurred in 1.7% of patients, including one patient who died due to tumor lysis syndrome. Among the 32 patients with hyperuricemic adverse reactions, 34% required urate-lowering medication to reduce uric acid levels, 6% required dose reduction and 6% required dose interruption. Hyperuricemia resolved in 73% of patients following initiation of urate-lowering medication without interruption or dose reduction of ROZLYTREK. No patients discontinued ROZLYTREK due to hyperuricemia.

Assess serum uric acid levels prior to initiating ROZLYTREK and periodically during treatment. Monitor patients for signs and symptoms of hyperuricemia. Initiate treatment with urate-lowering medications as clinically indicated and withhold ROZLYTREK for signs and symptoms of hyperuricemia. Resume ROZLYTREK at same or reduced dose upon improvement of signs or symptoms based on severity [see Dosage and Administration (2.4)].

## 5.6 QT INTERVAL PROLONGATION

Among the 355 patients who received ROZLYTREK across the clinical trials, 3.1% of patients with at least one post-baseline ECG assessment experienced QTcF interval prolongation of > 60 ms after starting ROZLYTREK and 0.6% had a QTcF interval > 500 ms [see Adverse Reactions (6.1), Clinical Pharmacology (12.2)].

Monitor patients who already have or who are at significant risk of developing QTc interval prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QT prolongation. Assess QT interval and electrolytes at baseline and periodically during treatment, adjusting frequency based upon risk factors such as congestive heart failure, electrolyte abnormalities, or concomitant medications known to prolong the QTc interval. Based on the severity of QTc interval prolongation, withhold ROZLYTREK and then resume at same or reduced dose, or permanently discontinue *[see Dosage and Administration (2.4)]*.

## 5.7 VISION DISORDERS

Among the 355 patients who received ROZLYTREK across clinical trials, vision changes occurred in 21% of patients, including Grade 1 (17%), Grade 2 (2.8%) and Grade 3 (0.8%) [see Adverse Reactions (6.1)]. Vision disorders occurring in  $\geq$  1% included blurred vision (9%), photophobia (5%), diplopia (3.1%), visual impairment (2%), photopsia (1.1%), cataract (1.1%), and vitreous floaters (1.1%).

For patients with new visual changes or changes that interfere with activities of daily living, withhold ROZLYTREK until improvement or stabilization and conduct an ophthalmological evaluation as clinically appropriate. Upon improvement or stabilization, resume ROZLYTREK at same or reduced dose *[see Dosage and Administration (2.4)]*.

## 5.8 EMBRYO-FETAL TOXICITY

Based on literature reports in humans with congenital mutations leading to changes in TRK signaling, findings from animal studies, and its mechanism of action, ROZLYTREK can cause fetal harm when administered to a pregnant woman. Administration of entrectinib to pregnant rats resulted in malformations at exposures approximately 2.7 times the human exposure at the 600 mg dose based on area under the curve (AUC).

Advise pregnant women of the potential risk to a fetus. Advise female patients of reproductive potential to use effective contraception during treatment with ROZLYTREK and for 5 weeks following the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with ROZLYTREK and for 3 months after the final dose *[see Use in Specific Populations (8.1, 8.3)]*.

**5.9 ROZLYTREK CONTAINS LACTOSE**. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

## 6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

- Congestive Heart Failure [see Warnings and Precautions (5.1)]
- Central Nervous System Effects [see Warnings and Precautions (5.2)]
- Skeletal Fractures [see Warnings and Precautions (5.3)]
- Hepatotoxicity [see Warnings and Precautions (5.4)]
- Hyperuricemia [see Warnings and Precautions (5.5)]
- QT Interval Prolongation [see Warnings and Precautions (5.6)]
- Vision Disorders [see Warnings and Precautions (5.7)]

## 6.1 CLINICAL TRIAL EXPERIENCE

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Data in WARNINGS AND PRECAUTIONS and below reflect exposure to ROZLYTREK in 355 patients, including 172 (48%) patients exposed for 6 months or longer and 84 (24%) patients exposed for 1 year or longer. ROZLYTREK was studied in one dose-finding trial in adults [ALKA (n = 57)], one dose-finding and activity-estimating trial in adults [STARTRK-1 (n = 76)], one dose-finding and activity-estimating trial in pediatric and adult patients [STARTRK-NG (n = 16)], and one single arm, activity-estimating trial in adults [STARTRK-2 (n = 206)].

The population characteristics were: median age 55 years (range: 4 to 86 years); 5% (n = 17) were less than 18 years of age; 55% were female; and 66% were White, 23% were Asian, and 5% were Black; 3% were Hispanic/Latino. The most common tumors ( $\geq$  5%) were lung (56%), sarcoma (8%), and colon (5%). *ROS1* gene fusions were present in 42% and *NTRK* gene fusions were present in 20%. Most adults (75%) received ROZLYTREK 600 mg orally once daily. The doses ranged from 100 mg/m<sup>2</sup> to 1600 mg/m<sup>2</sup> once daily in adults. ROZLYTREK is not indicated for patients less than 18 years of age [see Use in Specific Populations (8.4)].

Serious adverse reactions occurred in 39% of patients. The most frequent serious adverse reactions ( $\geq 2\%$ ) were pneumonia (3.9%), dyspnea (3.7%), pleural effusion (3.4%), sepsis (2.5%), pulmonary embolism (2.3%), respiratory failure (2%), and pyrexia (2%). Grade 3 or 4 adverse reactions occurred in 60% of patients; the most common ( $\geq 2\%$ ) were lung infection (5%), increased weight (7%), dyspnea (6%), fatigue/asthenia (5%), cognitive disorders (4.5%), syncope (2.5%), pulmonary embolism (3.4%), hypoxia (3.4%), pleural effusion (3.1%), hypotension (2.8%), diarrhea (2%), and urinary tract infection (2.5%). Fatal events included dyspnea (0.6%), pneumonia (0.6%), sepsis (0.6%), completed suicide (0.3%), large intestine perforation (0.3%) and tumor lysis syndrome (0.3%). One patient developed Grade 4 myocarditis after one dose of ROZLYTREK which resolved after discontinuation of ROZLYTREK and administration of high-dose corticosteroids.

Permanent discontinuation due to an adverse reaction occurred in 9% of patients who received ROZLYTREK. The most frequent adverse reactions (< 1% each) that resulted in permanent discontinuation were pneumonia, cardio-respiratory arrest, dyspnea, and fatigue.

Dose interruptions due to adverse reactions occurred in 46% of patients. The most frequent adverse reactions ( $\geq 2\%$ ) that resulted in interruption were increased blood creatinine (4%), fatigue (3.7%), anemia (3.1%), diarrhea (2.8%), pyrexia (2.8%), dizziness (2.5%), dyspnea (2.3%), nausea (2.3%), pneumonia (2.3%), cognitive disorder (2%) and neutropenia (2%).

Dose reductions due to adverse reactions occurred in 29% of patients who received ROZLYTREK. The most frequent adverse reactions resulting in dose reductions ( $\geq 1\%$ ) were dizziness (3.9%), increased blood creatinine (3.1%), fatigue (2.3%), anemia (1.7%), and increased weight (1.4%).

The most common adverse reactions ( $\geq 20\%$ ) were fatigue, constipation, dysgeusia, edema, dizziness, diarrhea, nausea, dysesthesia, dyspnea, myalgia, cognitive impairment, increased weight, cough, vomiting, pyrexia, arthralgia and vision disorders.

Table 3 summarizes the adverse reactions observed in these 355 patients.

# Table 3: Adverse Reactions (≥ 10%) in Patients Receiving ROZLYTREK in ALKA, STARTRK-1, STARTRK-2, and STARTRK-NG

Adverse Reactions	ROZLYTREK N = 355		
	All Grades (%)	Grade ≥ 3* (%)	
General			
Fatigue <sup>1</sup>	48	5	
Edema <sup>2</sup>	40	1.1	
Pyrexia	21	0.8	
Gastrointestinal			
Constipation	46	0.6	
Diarrhea	35	2.0	
Nausea	34	0.3	
Vomiting	24	0.8	
Abdominal pain <sup>3</sup>	16	0.6	
Nervous System			
Dysgeusia	44	0.3	
Dizziness <sup>4</sup>	38	0.8	
Dysesthesia <sup>5</sup>	34	0.3	
Cognitive impairment <sup>6</sup>	27	4.5	
Peripheral sensory neuropathy <sup>7</sup>	18	1.1	
Headache	18	0.3	
Ataxia <sup>8</sup>	17	0.8	
Sleep <sup>9</sup>	14	0.6	
Mood disorders <sup>10</sup>	10	0.6	
<b>Respiratory, Thoracic and Mediastinal</b>		•	
Dyspnea	30	6*	
Cough	24	0.3	
Musculoskeletal and Connective Tissue			
Myalgia <sup>11</sup>	28	1.1	
Arthralgia	21	0.6	
Muscular weakness	12	0.8	
Back pain	12	1	
Pain in extremity	11	0.3	
Metabolism and Nutritional		,	
Increased weight	25	7	
Decreased appetite	13	0.3	
Dehydration	10	1.1	
Eye			
Vision disorders <sup>12</sup>	21	0.8	
Infections			
Urinary tract infection	13	2.3	
Lung infection <sup>13</sup>	10	6*	
Vascular			
Hypotension <sup>14</sup>	18	2.8	
Skin and Subcutaneous Tissue		-	
Rash <sup>15</sup>	11	0.8	

\* Grades 3 – 5, inclusive of fatal adverse reactions, including 2 events of pneumonia and 2 events of dyspnea.

<sup>1</sup>Includes fatigue, asthenia

<sup>2</sup> Includes face edema, fluid retention, generalized edema, localized edema, edema, edema peripheral, peripheral swelling

<sup>3</sup> Includes abdominal pain upper, abdominal pain, lower abdominal discomfort, abdominal tenderness

<sup>4</sup> Includes dizziness, vertigo, dizziness postural

Adverse Reactions	ROZLYTREK N = 355	
	All Grades (%)         Grade ≥ 3* (%)	
5 7 1 1		

<sup>5</sup> Includes paresthesia, hyperesthesia, hypoesthesia, dysesthesia, oral hypoesthesia, palmar-plantar erythrodysesthesia, oral paresthesia, genital hypoesthesia

<sup>6</sup> Includes amnesia, aphasia, cognitive disorder, confusional state, delirium, disturbance in attention, hallucinations, visual hallucination, memory impairment, mental disorder, mental status changes

<sup>7</sup> Includes neuralgia, neuropathy peripheral, peripheral motor neuropathy, peripheral sensory neuropathy

<sup>8</sup> Includes ataxia, balance disorder, gait disturbances

<sup>9</sup> Includes hypersomnia, insomnia, sleep disorder, somnolence

<sup>10</sup> Includes anxiety, affect lability, affective disorder, agitation, depressed mood, euphoric mood, mood altered, mood swings,

irritability, depression, persistent depressive disorder, psychomotor retardation

<sup>11</sup> Includes musculoskeletal pain, musculoskeletal chest pain, myalgia, neck pain

<sup>12</sup> Includes blindness, cataract, cortical cataract, corneal erosion, diplopia, eye disorder, photophobia, photopsia, retinal

hemorrhage, vision blurred, visual impairment, vitreous adhesions, vitreous detachment, vitreous floaters

<sup>13</sup> Includes lower respiratory tract infection, lung infection, pneumonia, respiratory tract infection

<sup>14</sup> Includes hypotension, orthostatic hypotension

<sup>15</sup> Includes rash, rash maculopapular, rash pruritic, rash erythematous, rash papular

Clinically relevant adverse reactions occurring in  $\leq 10\%$  of patients include dysphagia (10%), fall (8%), pleural effusion (8%), fractures (6%), hypoxia (4.2%), pulmonary embolism (3.9%), syncope (3.9%), congestive heart failure (3.4%), and QT prolongation (3.1%).

Table 4 summarizes the laboratory abnormalities.

# Table 4: Laboratory Abnormalities (≥ 20%) Worsening from Baseline in Patients Receiving ROZLYTREK in ALKA, STARTRK-1, STARTRK-2, and STARTRK-NG

Laboratory Abnormality	ROZLYTREK NCI CTCAE Grade		
	All Grades (%) <sup>1</sup>	<b>Grade 3 or 4 (%)</b> <sup>1</sup>	
Hematology			
Anemia	67	9	
Lymphopenia	40	12	
Neutropenia	28	7	
Chemistry			
Increased creatinine <sup>2</sup>	73	2.1	
Hyperuricemia	52	10	
Increased AST	44	2.7	
Increased ALT	38	2.9	
Hypernatremia	35	0.9	
Hypocalcemia	34	1.8	
Hypophosphatemia	30	7	
Increased lipase	28	10	
Hypoalbuminemia	28	2.9	
Increased amylase	26	5.4	
Hyperkalemia	25	1.5	
Increased alkaline phosphatase	25	0.9	
Hyperglycemia <sup>3</sup>	NE <sup>3</sup>	3.8	

AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase

<sup>1</sup> Denominator for each laboratory parameter is based on the number of patients with a baseline and post-treatment laboratory value available which ranged from 111 to 346 patients.

<sup>2</sup> Based on NCI CTCAE v5.0

 $^{3}$  NE = Not evaluable. Grade 1 and 2 could not be determined per NCI CTCAE v5.0, as fasting glucose values were not collected.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form: <u>https://sideeffects.health.gov.il/</u>

## 7 DRUG INTERACTIONS

## 7.1 EFFECT OF OTHER DRUGS ON ROZLYTREK

### Moderate and Strong CYP3A Inhibitors

Coadministration of ROZLYTREK with a strong or moderate CYP3A inhibitor increases entrectinib plasma concentrations *[see Clinical Pharmacology (12.3)]*, which could increase the frequency or severity of adverse reactions. Avoid coadministration of strong or moderate CYP3A inhibitors with ROZLYTREK. If coadministration is unavoidable, reduce the ROZLYTREK dose *[see Dosage and Administration (2.5), Clinical Pharmacology (12.3)]*.

Avoid grapefruit products during treatment with ROZLYTREK, as they contain inhibitors of CYP3A.

#### Moderate and Strong CYP3A Inducers

Coadministration of ROZLYTREK with a strong or moderate CYP3A inducer decreases entrectinib plasma concentrations *[see Clinical Pharmacology (12.3)]*, which may reduce ROZLYTREK efficacy. Avoid coadministration of strong and moderate CYP3A inducers with ROZLYTREK.

### 7.2 Drugs That Prolong QT Interval

QTc interval prolongation can occur with ROZLYTREK. Avoid coadministration of ROZLYTREK with other products with a known potential to prolong QT/QTc interval *[see Warnings and Precautions (5.6), Clinical Pharmacology (12.2)]*.

## 8 USE IN SPECIFIC POPULATIONS

## 8.1 **PREGNANCY**

#### Risk Summary

Based on literature reports in humans with congenital mutations leading to changes in TRK signaling, findings from animal studies, and its mechanism of action *[see Clinical Pharmacology (12.1)]*, ROZLYTREK can cause fetal harm when administered to a pregnant woman. There are no available data on ROZLYTREK use in pregnant women. Administration of entrectinib to pregnant rats during the period of organogenesis resulted in malformations at maternal exposures approximately 2.7 times the human exposure at the 600 mg dose *(see Data)*. Advise pregnant women of the potential risk to a fetus.

Data

#### Human Data

Published reports of individuals with congenital mutations in TRK pathway proteins suggest that decreases in TRK-mediated signaling are correlated with obesity, developmental delays, cognitive impairment, insensitivity to pain, and anhidrosis.

#### Animal Data

Entrectinib administration to pregnant rats during the period of organogenesis at a dose of 200 mg/kg [resulting in exposures up to 2.7 times the human exposure (AUC) at the 600 mg dose] resulted in maternal toxicity and

fetal malformations including body closure defects (omphalocele and gastroschisis) and malformations of the vertebrae, ribs, and limbs (micromelia and adactyly), but not embryolethality. Lower fetal weights and reduced skeletal ossification occurred at doses  $\geq$  12.5 and 50 mg/kg [approximately 0.2 and 0.9 times the human exposure (AUC) at the 600 mg dose], respectively.

# 8.2 LACTATION

## Risk Summary

There are no data on the presence of entrectinib or its metabolites in human milk or their effects on either the breastfed child or on milk production. Because of the potential adverse reactions in breastfed children from ROZLYTREK, advise a lactating woman to discontinue breastfeeding during treatment with ROZLYTREK and for 7 days after the final dose.

# 8.3 FEMALES AND MALES OF REPRODUCTIVE POTENTIAL

## Pregnancy Testing

Verify the pregnancy status of females of reproductive potential prior to initiating ROZLYTREK [see Use in Specific Populations (8.1)].

## Contraception

ROZLYTREK can cause embryo-fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].

## Females

Advise female patients of reproductive potential to use effective contraception during treatment with ROZLYTREK and for at least 5 weeks following the final dose [see Use in Specific Populations (8.1)].

## Males

Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ROZLYTREK and for 3 months following the final dose [see Nonclinical Toxicology (13.1)].

## 8.4 PEDIATRIC USE

ROZLYTREK is not indicated for patients less than 18 years of age.

## 8.5 GERIATRIC USE

Of the 355 patients who received ROZLYTREK across clinical trials, 25% were 65 years or older, and 5% were 75 years of age or older. Clinical studies of ROZLYTREK did not include sufficient numbers of geriatric patients to determine whether they respond differently from younger patients.

# 8.6 RENAL IMPAIRMENT

No dose adjustment is recommended for patients with mild or moderate renal impairment (CLcr 30 to < 90 mL/min calculated by Cockcroft-Gault equation). ROZLYTREK has not been studied in patients with severe renal impairment (CLcr < 30 mL/min) [see Clinical Pharmacology (12.3)].

## 8.7 HEPATIC IMPAIRMENT


No dose adjustment is recommended for patients with mild (total bilirubin  $\leq 1.5$  times ULN) hepatic impairment. ROZLYTREK has not been studied in patients with moderate (total bilirubin > 1.5 to 3 times ULN) and severe (total bilirubin > 3 times ULN) hepatic impairment [see Clinical Pharmacology (12.3)].

# **11 DESCRIPTION**

Entrectinib is a kinase inhibitor. The molecular formula for entrectinib is  $C_{31}H_{34}F_2N_6O_2$  and the molecular weight is 560.64 Daltons. The chemical name is N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-

methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide. The chemical structure of entrectinib is as follows:

Entrectinib is white to pale pink powder.



ROZLYTREK (entrectinib) capsules for oral use are supplied as printed hard-shell capsules containing 100 mg (yellow opaque HPMC capsule) or 200 mg of entrectinib (orange opaque HPMC capsule).

Inactive ingredients:

- *Capsule content:* lactose anhydrous, tartaric acid, crospovidone, hypromellose, microcrystalline cellulose, magnesium stearate, colloidal silicon dioxide.
- *Capsule shell:* hypromellose, titanium dioxide (E171), yellow iron oxide (E172; for Rozlytrek 100 mg capsule), FD&C Yellow #6 (E110; for Rozlytrek 200 mg capsule).
- Printing ink: shellac, propylene glycol, strong ammonia solution, and FD&C blue #2 aluminum lake.

## 12 CLINICAL PHARMACOLOGY

## **12.1 MECHANISM OF ACTION**

Entrectinib is an inhibitor of the tropomyosin receptor tyrosine kinases (TRK) TRKA, TRKB, and TRKC (encoded by the neurotrophic tyrosine receptor kinase [*NTRK*] genes *NTRK1*, *NTRK2*, and *NTRK3*, respectively), proto-oncogene tyrosine-protein kinase ROS1 (ROS1), and anaplastic lymphoma kinase (ALK) with IC<sub>50</sub> values of 0.1 to 2 nM. Entrectinib also inhibits JAK2 and TNK2 with IC<sub>50</sub> values > 5 nM. The major active metabolite of entrectinib, M5, showed similar in vitro activity against TRK, ROS1, and ALK.

Fusion proteins that include TRK, ROS1, or ALK kinase domains can drive tumorigenic potential through hyperactivation of downstream signaling pathways leading to unconstrained cell proliferation. Entrectinib demonstrated in vitro and in vivo inhibition of cancer cell lines derived from multiple tumor types harboring *NTRK*, *ROS1*, and *ALK* fusion genes.

Entrectinib demonstrated steady-state brain-to-plasma concentration ratios of 0.4 - 2.2 in multiple animal species (mice, rats, and dogs) and demonstrated in vivo anti-tumor activity in mice with intracranial implantation of TRKA- and ALK-driven tumor cell lines.

## **12.2 PHARMACODYNAMICS**

Entrectinib exposure-response relationships and the time course of pharmacodynamic responses are unknown.

## Cardiac Electrophysiology

Across clinical trials, 3.1% of 355 patients, who received ROZLYTREK at doses ranging from 100 mg to 2600 mg daily under fasting or fed conditions (75% received 600 mg orally once daily) and had at least one post-baseline ECG assessment, experienced QTcF interval prolongation of > 60 ms after starting ROZLYTREK and 0.6% had a QTc interval > 500 ms [see Warnings and Precautions (5.6)].

## **12.3 PHARMACOKINETICS**

The pharmacokinetics for entrectinib and its pharmacologically active major circulating metabolite M5 were characterized in adult patients with *ROS1*-positive NSCLC, *NTRK* gene fusion-positive solid tumors, and healthy subjects. The pharmacokinetics of entrectinib and M5 are linear and are not dose-dependent or time-dependent. Steady state is achieved within one week for entrectinib and two weeks for M5 following daily administration of ROZLYTREK. The pharmacokinetic parameters for entrectinib and M5 are described in Table 5.

Parameter	Entrectinib Mean* (% CV)	M5 Mean* (% CV)
AUC <sub>D1</sub> (nM*h)	31800 (48%)	10200 (82%)
AUC <sub>ss</sub> (nM*h)	48000 (77%)	24000 (97%)
C <sub>maxD1</sub> (nM)	2250 (58%)	622 (79%)
C <sub>maxss</sub> (nM)	3130 (80%)	1250 (90%)
R <sub>acc(AUC)</sub>	1.55 (49%)	2.84 (93%)

<b>Table 5: Pharmacokinetic</b>	<b>Parameters</b> for	Entrectinib a	and Metabolite M5
i ubie of i nui mucommetie	1 al aniceel 5 101	Linti ettimito t	

\* Geometric mean

### Absorption

The maximum entrectinib plasma concentration was reached 4 - 6 hours after oral administration of a 600 mg dose.

## Effect of Food

A high-fat (approximately 50% of total caloric content), high-calorie (approximately 800 to 1000 calories) meal did not have a significant effect on entrectinib exposure.

## Distribution

Entrectinib and its active major metabolite M5 are both > 99% bound to human plasma proteins in vitro.

The estimated apparent volume of distribution (V/F) was 551 L and 81.1 L for entrectinib and M5, respectively.

#### Elimination

The estimated apparent clearance (CL/F) was 19.6 L/h and 52.4 L/h for entrectinib and M5, respectively. The elimination half-lives of entrectinib and M5 were estimated to be 20 and 40 hours, respectively.

#### Metabolism

Entrectinib is metabolized primarily by CYP3A4 (~76%). The active metabolite M5 (formed by CYP3A4) is the only major active circulating metabolite identified. M5 has similar pharmacological potency to entrectinib in vitro and circulating M5 exposures at steady-state in patients were 40% of the corresponding entrectinib exposure.

#### Excretion

Following oral administration of a single oral dose of  $[^{14}C]$ -labeled entrectinib, 83% of radioactivity was excreted in feces (36% of the dose as unchanged entrectinib and 22% as M5) with minimal excretion in urine (3%).

#### Specific Populations

No clinically significant differences in the pharmacokinetics of entrectinib were observed based on age (12 years to 86 years), sex, race (White, Asian and Black), body weight (32 to 130 kg), mild to moderate renal impairment (CLcr 30 to < 90 mL/min) and mild hepatic impairment (total bilirubin  $\leq$  1.5 times ULN). The impact of

moderate to severe hepatic impairment or severe renal impairment on the pharmacokinetics of entrectinib is unknown.

## Drug Interaction Studies

## Clinical Studies

*Effect of CYP3A Inhibitors on Entrectinib:* Coadministration of itraconazole (a strong CYP3A inhibitor) with a single 100 mg ROZLYTREK dose increased entrectinib AUC<sub>0-INF</sub> by 6-fold and  $C_{max}$  by 1.7-fold *[see Drug Interactions (7.1)]*. Coadministration of a moderate CYP3A inhibitor with ROZLYTREK is predicted to increase entrectinib AUC<sub>0-Tau</sub> by 3-fold and  $C_{max}$  by 2.9-fold.

*Effect of CYP3A Inducers on Entrectinib:* Coadministration of rifampin (a strong CYP3A inducer) with a single 600 mg ROZLYTREK dose reduced entrectinib AUC<sub>0-INF</sub> by 77% and C<sub>max</sub> by 56% *[see Drug Interactions (7.1)]*. Coadministration of a moderate CYP3A inducer with ROZLYTREK is predicted to reduce entrectinib AUC<sub>0-Tau</sub> by 56% and C<sub>max</sub> by 43%.

*Effect of Gastric Acid Reducing Drugs on Entrectinib*: Coadministration of a proton pump inhibitor (PPI), lansoprazole with a single 600 mg ROZLYTREK dose reduced entrectinib AUC by 25% and C<sub>max</sub> by 23%.

*Effect of Entrectinib on CYP Substrates*: Coadministration of ROZLYTREK 600 mg once daily with oral midazolam (a sensitive CYP3A substrate) in patients increased the midazolam AUC by 50% but reduced midazolam C<sub>max</sub> by 21% [see Drug Interactions (7.1)].

*Effect of Entrectinib on Transporters:* Coadministration of a single 600 mg ROZLYTREK dose with digoxin [a sensitive P-glycoprotein (P-gp) substrate] increased digoxin C<sub>max</sub> by 28% and AUC by 18%.

## In Vitro Studies

Entrectinib is not a substrate of P-gp or BCRP, but M5 is a substrate of P-gp and BCRP. Entrectinib and M5 are not substrates of OATP1B1 or OATP1B3.

# 13 NONCLINICAL TOXICOLOGY

# 13.1 CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY

Carcinogenicity studies were not conducted with entrectinib. Entrectinib was not mutagenic in vitro in the bacterial reverse mutation (Ames) assay; however, an in vitro assay in cultured human peripheral blood lymphocytes did demonstrate a potential for abnormal chromosome segregation (aneugenicity). Entrectinib was not clastogenic or aneugenic in the in vivo micronucleus assay in rats and did not induce DNA damage in a comet assay in rats.

Dedicated fertility studies were not conducted with entrectinib. With the exception of dose-dependent decreases in prostate weight in male dogs, there were no effects on male and female reproductive organs observed in general toxicology studies conducted in rats and dogs at doses resulting in exposures of up to approximately 3.2 fold the human exposure (AUC) at the 600 mg dose.

# 14 CLINICAL STUDIES

# 14.1 ROS1-POSITIVE NON-SMALL CELL LUNG CANCER

The efficacy of ROZLYTREK was evaluated in a pooled subgroup of patients with *ROS1*-positive metastatic NSCLC who received ROZLYTREK at various doses and schedules (90% received ROZLYTREK 600 mg orally once daily) and were enrolled in one of three multicenter, single-arm, open-label clinical trials: ALKA, STARTRK-1 (NCT02097810) and STARTRK-2 (NCT02568267). To be included in this pooled subgroup, patients were required to have histologically confirmed, recurrent or metastatic, *ROS1*-positive NSCLC, ECOG performance status  $\leq 2$ , measurable disease per RECIST v 1.1,  $\geq 18$  months of follow-up from first post-treatment tumor assessment, and no prior therapy with a ROS1 inhibitor. Identification of *ROS1* gene fusion in tumor specimens was prospectively determined in local laboratories using either a fluorescence in situ

hybridization (FISH),next-generation sequencing (NGS),or polymerase chain reaction (PCR) laboratorydeveloped tests. All patients were assessed for CNS lesions at baseline. The major efficacy outcome measures were overall response rate (ORR) and duration of response (DOR) according to RECIST v1.1 as assessed by blinded independent central review (BICR). Intracranial response according to RECIST v1.1 was assessed by BICR. Tumor assessments with imaging were performed every 8 weeks.

Efficacy was assessed in 92 patients with *ROS1*-positive NSCLC. The median age was 53 years (range: 27 to 86); female (65%); White (48%), Asian (45%), and Black (5%); and Hispanic or Latino (2.4%); never smoked (59%); and ECOG performance status 0 or 1 (88%). Ninety-nine percent of patients had metastatic disease, including 42% with CNS metastases; 96% had adenocarcinoma; 65% received prior platinum-based chemotherapy for metastatic or recurrent disease and no patient had progressed in less than 6 months following platinum-based adjuvant or neoadjuvant therapy. *ROS1* positivity was determined by NGS in 79%, FISH in 16%, and PCR in 4%. Twenty-five percent had central laboratory confirmation of *ROS1* positivity using an analytically validated NGS test.

Efficacy results are summarized in Table 6.

· ·	1	
Efficacy Parameters	ROZLYTREK N = 92	
<b>Overall Response Rate</b> (95% CI)	74% (64, 83)	
Complete Response	15%	
Partial Response	59%	
Duration of Response (DOR)*	N = 68	
Range (months)	2.4, 55.2+	
% DOR $\geq$ 9 months	75%	
% DOR $\geq$ 12 months	57%	

Table 6: Efficacy Results in ROS1-Positive NSCLC Patients per BICR Assessment

Confidence Interval (CI) calculated using the Clopper-Pearson method.

\* Observed DOR

+ denotes ongoing response

% DOR  $\geq$  18 months

Among the 92 patients, 10 had measurable CNS metastases at baseline as assessed by BICR and had not received radiation therapy to the brain within 2 months prior to study entry. Responses in intracranial lesions were observed in 7 of these 10 patients.

38%

# 14.2 NTRK GENE FUSION-POSITIVE SOLID TUMORS

The efficacy of ROZLYTREK was evaluated in a pooled subgroup of adult patients with unresectable or metastatic solid tumors with a *NTRK* gene fusion enrolled in one of three multicenter, single-arm, open-label clinical trials: ALKA, STARTRK-1 (NCT02097810) and STARTRK-2 (NCT02568267). To be included in this pooled subgroup, patients were required to have progressed following systemic therapy for their disease, if available, or would have required surgery causing significant morbidity for locally advanced disease; measurable disease per RECIST v1.1; at least 2 years of follow-up from first post-treatment tumor assessment; and no prior therapy with a TRK inhibitor. Patients received ROZLYTREK at various doses and schedules (94% received ROZLYTREK 600 mg orally once daily) until unacceptable toxicity or disease progression. Identification of positive *NTRK* gene fusion status was prospectively determined in local laboratories or a central laboratory using various nucleic acid-based tests. The major efficacy outcome measures were ORR and DOR, as determined by a BICR according to RECIST v1.1. Intracranial response according to RECIST v1.1 as evaluated by BICR. Tumor assessments with imaging were performed every 8 weeks.

Efficacy was assessed in the first 54 adult patients with solid tumors with an *NTRK* gene fusion enrolled into these trials. The median age was 58 years (range: 21 to 83); female (59%); White (80%), Asian (13%) and Hispanic or Latino (7%); and ECOG performance status 0 (43%) or 1 (46%). Ninety-six percent of patients had metastatic disease, including 22% with CNS metastases, and 4% had locally advanced, unresectable disease. All

patients had received prior treatment for their cancer including surgery (n = 43), radiotherapy (n = 36), or systemic therapy (n = 48). Forty patients (74%) received prior systemic therapy for metastatic disease with a median of 1 prior systemic regimen and 17% (n = 9) received 3 or more prior systemic regimens. The most common cancers were sarcoma (24%), lung cancer (19%), salivary gland tumors (13%), breast cancer (11%), thyroid cancer (9%), and colorectal cancer (7%). A total of 52 (96%) patients had an *NTRK* gene fusion detected by NGS and 2 (4%) had an *NTRK* gene fusion detected by other nucleic acid-based tests. Eighty-three percent of patients had central laboratory confirmation of *NTRK* gene fusion using an analytically validated NGS test.

Efficacy results are summarized in Tables 7, 8, and 9.

Efficacy Parameter	ROZLYTREK N = 54
<b>Overall Response Rate</b> (95% CI)	59% (45, 72)
Complete Response	13%
Partial Response	46%
Duration of Response*	N = 32
Range (months)	2.8, 47.8+
% with duration $\geq 6$ months	72%
% with duration $\geq$ 9 months	66%
% with duration $\geq 12$ months	56%

\* Observed DOR

+ denotes ongoing response

#### Table 8: Efficacy by Tumor Type

	Patients	0	DOR	
Tumor Type	N = 54	%	95% CI	Range (months)
Sarcoma	13	46%	19%, 75%	2.8, 33.6+
Non-small cell lung cancer	10	60%	26%, 88%	3.7, 47.8+
Salivary (MASC)	7	86%	42%, 100%	2.8, 38.5+
Breast cancer	6	83%	36%, 100%	4.2, 42.3+
Thyroid cancer	5	60%	NA	7.9, 31.5+
Colorectal cancer	4	25%	NA	15.1
Neuroendocrine cancers	3	CR	NA	32.9+
Pancreatic cancer	3	PR, PR	NA	7.1, 12.9
Gynecological cancers	2	PR	NA	38.2
Cholangiocarcinoma	1	PR	NA	9.3

+ denotes ongoing response

MASC: mammary analogue secretory carcinoma; NA = not applicable; PR = partial response.

#### Table 9: Efficacy Results by NTRK Gene Fusion Partner

NTRK Partner	Patients N = 54	ORR		DOR	
		%	95% CI	Range (months)	
ETV6 – NTRK3	25	72%	51%, 88%	2.8, 47.8+	
TPM3 – NTRK1	4	50%	7%, 93%	2.8, 15.1	
TPR – NTRK1	4	100%	40%, 100%	5.6, 33.6+	
LMNA – NTRK1	2	PR, PD	NA	4.2	
SQSTM1 – NTRK1	2	PR, PD	NA	18.8+	
PEAR1 – NTRK1	2	SD, NE	NA	NA	
EML4 – NTRK3	2	PR, NE	NA	13.2	
CD74 – NTRK1	1	PR	NA	10.4	

		1		
PLEKHA6 – NTRK1	1	PR	NA	9.3
CDC42BPA – NTRK1	1	PR	NA	29.4
EPS15L1 – NTRK1	1	PR	NA	3.7
RBPMS – NTRK3	1	PR	NA	4.6
ERC1 – NTRK1	1	SD	NA	NA
PDIA3 – NTRK1	1	SD	NA	NA
TRIM33 – NTRK1	1	SD	NA	NA
AKAP13 – NTRK3	1	SD	NA	NA
KIF7 – NTRK3	1	SD	NA	NA
FAM19A2 – NTRK3	1	PD	NA	NA
CGN – NTRK1	1	NE	NA	NA
SQSTM1 – NTRK2	1	NE	NA	NA

+ denotes ongoing response PR = partial response; PD = progressive disease; SD = stable disease; NA = not applicable; NE = not evaluable.

Among the subset of patients who received prior systemic therapy for metastatic disease, the ORR was 53%, similar to that seen in the overall population. Among the 54 adult patients, 4 had measurable CNS metastases at baseline as assessed by BICR and had not received radiation therapy to the brain within 2 months of study entry. Responses in intracranial lesions were observed in 3 of these 4 patients.

### 16 HOW SUPPLIED/STORAGE AND HANDLING

- 100 mg hard capsules: Size 2 yellow opaque, with "ENT 100" printed in blue ink; available in: HDPE bottles containing 30 hard capsules with a child-resistant, tamper-evident closure and silica gel desiccant integrated in the cap.
- 200 mg hard capsules: Size 0 orange opaque, with "ENT 200" printed in blue ink; available in: HDPE bottles containing 90 hard capsules with a child-resistant, tamper-evident closure and silica gel desiccant integrated in the cap.

Store below 30°C.

## **17. SHELF LIFE**

The expiry date of the product is indicated on the packaging materials

#### **18. MARKETING AUTHORISATION HOLDER**

Roche Pharmaceuticals (Israel) Ltd., P.O.Box 6391 Hod Hasharon 4524079.

## **19. MARKETING AUTHORISATION NUMBER(S)**

#### Rozlytrek 100 mg hard capsules; 36185

#### Rozlytrek 200 mg hard capsules: 36186

#### **20. MANUFACTURER**

F. Hoffmann-La Roche Ltd., Basel, Switzerland.

#### Revised on Dec-2021 according to MOHs guidelines.